Positive Phase 3 Data for COMP360: Durable 26-Week Benefit, Q4 NDA Submission Confirmed
CMPS has more than doubled off its 52-week low of $3.24.
Summary
COMPASS Pathways reported strong 26-week results from its Phase 3 COMP006 trial for COMP360 in treatment-resistant depression, showing rapid onset and durable clinical benefit. Specifically, 39% of patients receiving the 25 mg dose achieved a significant reduction in depression scores by Week 6, maintaining this benefit through Week 26. This positive data is a major de-risking event for the company's lead psychedelic therapy, significantly boosting its path to market. The company confirmed its rolling New Drug Application (NDA) submission remains on track for completion in Q4 2026, with a potential launch in the first half of 2027.
At the time of this announcement, CMPS was trading at $13.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $3.24 to $15.40. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.